Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KRTEV
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Monoclonal antibody B43-genistein-conjugate
|
|||||
| Synonyms |
B43-Gen; B43-Genistein; B43-Genistein conjugate; Monoclonal antibody B43-Gen; Monoclonal antibody B43-genistein-conjugate
Click to Show/Hide
|
|||||
| Organization |
University of Minnesota; Bristol Myers Squibb Co.
|
|||||
| Drug Status |
Phase 1 (Terminated)
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
Undisclosed
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
B-lymphocyte antigen CD19 (CD19)
|
Antigen Info | ||||
| Payload Name |
Genistein
|
Payload Info | ||||
| Therapeutic Target |
Pro-epidermal growth factor (EGF)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random Lysines
|
|||||
